drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody)
drug_description
Recombinant humanized anti-EGFR monoclonal antibody (IV) that binds EGFR’s extracellular domain to block ligand binding and receptor dimerization, suppress downstream signaling, and may engage Fc-mediated ADCC.
nci_thesaurus_concept_id
C178313
nci_thesaurus_definition
A human immunoglobulin G1 (IgG1) monoclonal antibody directed against human epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon administration, becotatug targets, binds to and prevents the activation of EGFR. This inhibits EGFR-mediated signaling and proliferation of EGFR-expressing tumor cells. In addition, JMT101 may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against EGFR-expressing tumor cells. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on various tumor cell types.
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody against EGFR that binds the receptor’s extracellular domain to block ligand binding and receptor dimerization, inhibiting EGFR-driven signaling and tumor cell proliferation, and may induce Fc-mediated ADCC against EGFR-expressing cells.
drug_name
JMT101
nct_id_drug_ref
NCT06735391